Group 1 - The core point of the article is that Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, leading to the termination of its major asset restructuring plan [2] - Nanjing Pharmaceutical signed an acquisition intention agreement with Future Pharmaceutical on August 26, 2025, which was expected to constitute a major asset restructuring according to relevant regulations [2] - The company has faced continuous revenue decline since its listing in 2020, with a significant loss of 357 million yuan in 2024 and a 71.28% year-on-year revenue drop in the first half of 2025 [3] Group 2 - As of September 30, Nanjing Pharmaceutical's stock price closed at 11.37 yuan per share, with a market capitalization of 3.12 billion yuan [7] - In the first half of 2025, the company reported revenue of 61.8463 million yuan and a net loss of 40.0023 million yuan, with a non-recurring net profit loss of 41.7314 million yuan [3]